the numbers of Copd (pulmonary disease, chronic obstructive), among the emergencies in the viewfinder of 20 thousand experts gathered in Vienna for the congress of the Società european respiratory (Ers). Against the serious disease, which, according to the world Organization of the sanità sarà by 2030 the third leading cause of death in the planet – is the examination of the authoritiesà regulatory Uses a new therapy to save the lungs.
it Is called roflumilast, and is according to the specialists, “a historical turn”.
For the first time, in fact, in addition to the classical bronchodilator, a medication to take by mouth reduces exacerbations and improves the functionalityà pulmonary.
novità that the ‘talking’ a bit’ of Italian: Leonardo Fabbri, university of Modena and Reggio Emilia is the author of two studies on the molecule.
The results of 4 multicenter clinical trials (two lasting 6 months, and two of a year) – to a note – have shown that roflumilast, a pill anti-inflammatory ‘once a day’ (a single daily administration) developed by the swiss Nycomed, in addition to improving the functionalityà pulmonary reduces in a statistically significant and clinically relevant (15-37%) exacerbations in patients with moderate to severe Copd, is also associated to the standard treatment.
The studies, conducted in 10 Countries including the Peninsula, involved the participation of the 4,500 patients.
“Roflumilast is an inhibitor of phosphodiesterase 4 (PDE4) and could represent an important new treatment for Copd – says Fernando Martinez Università of Michigan, main author of the studies lasted for 12 months – We need new alternatives for the patients and the results of these studies confirm the benefits hoped for. The new molecule, reduces exacerbations and improves the functionalityà of the lung, even in patients in which è very poor”.
The molecule, adds Fabbri, professor of respiratory medicine at the Università of Modena and Reggio Emilia and the main author of the trial of 6 months, “has a modeà on revolutionary action, and in the next few years may become the only alternative is completely new, and for the treatment of Copd.
The results confirm the important improvements, prolonged and statistically significant in the functionalityà of the lung, show that roflumilast has also revealed a tendency to reduce complications if given in addition to inhaled bronchodilators long-acting inhaled”, says the expert.
Cystitis: causes, symptoms and treatment
the Page was published on 14 September 2009